Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector

Cancer Gene Therapy

Volumn 5, Issue 3, 1998, Pages 158-162

  Rainov, Nikolai G ^a,b,c   Dobberstein, Karl Ulrich ^a   Heidecke, Volkmar ^a   Dorant, Ulrich ^a   Chase, Maureen ^b   Kramm, Christof M ^d   Chiocca, E Antonio ^b   Breakefield, Xandra O ^b,c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Brain neoplasms; Gene therapy; Herpes simplex virus type 1; Infra arterial application; Thymidine kinase

Indexed keywords

BRADYKININ; GANCICLOVIR;

ANIMAL; ARTICLE; BRAIN TUMOR; CANCER TRANSPLANTATION; DISEASE MODEL; FISCHER 344 RAT; GENE THERAPY; GENE VECTOR; GENETICS; GLIOSARCOMA; HERPES SIMPLEX VIRUS; INTRAARTERIAL DRUG ADMINISTRATION; MALE; RAT;

ANIMALS; BRADYKININ; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOSARCOMA; INJECTIONS, INTRA-ARTERIAL; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; SIMPLEXVIRUS;

EID: 0032067008     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54: 5745-5751.
2. Chen SH, Shine HD, Goodman JC, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
3. Chiocca EA, Andersen J, Takamiya Y, et al. Virus-mediated genetic treatment of rodent gliomas. In: Wolf JA. ed. Gene Therapeutics. Boston: Birkhauser; 1994:245-262.
4. Oldfield EH, Ram Z, Culver KW, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993;4:39-69.
5. Kramm CM, Sena-Esteves M, Barnett FH, et al. Gene therapy for brain tumors. Brain Pathol. 1995;5:345-381.
6. Berens ME, Rutka JT, Rosenblum ML. Brain tumor epidemiology, growth and invasion. Neurosurg Clin N Am. 1990;1:1-18.
7. Rainov NG, Zimmer C, Chase M, et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther. 1995;6:1543-1552.
8. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res. 1996;56:4264-4266.
9. Nilaver G, Muldoon LL, Kroll RA, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA. 1995;92:9829-9833.
10. Doran SE, Ren XD, Betz AL, et al. Gene expression from recombinant viral vectors in the CNS following bloodbrain-barrier disruption. Neurosurgery. 1995;36:965-970.
11. Neuwelt EA, Hill SA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol. 1987;4: 195-207.
12. Zünkeller B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg. 1996;85:1056-1065.
13. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 1acZ insertion mutant. J Virol. 1988;62:196-205.
14. Roizman B, Spear PG. Preparation of herpes simplex virus of high titer. J Virol. 1968;2:83-84.
15. Barba D, Hardin J, Ray J, et al. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg. 1993;79: 729-735.
16. Rainov NG, Kramm CM, Aboody-Guterman K, et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. 1996;3:99-106.
17. Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for treatment of brain tumors in rats. Cancer Res. 1994;53:83-88.
18. Kramm CM, Rainov NG, Sena-Esteves M, et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther. 1996;7:1989-1994.
19. Tapscott SJ, Miller AD, Olson JM, et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA. 1994;91:8185-8189.
20. Tzeng JJ, Barth RF, Orosz CG, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and non-immunogenic rat brain tumors. Cancer Res. 1991;51:2373-2378.
21. Holladay FP, Lopez GM, Morantz RA, et al. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery. 1992;30:499-504.
22. + cells localize selectively in rat 9L gliosarcomas but have reduced cytolytic function. Cancer Res. 1996;56: 3516-3525.
23. Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated cytokine-producing tumor cells stimulates CDS+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA. 1996;93:10399-10404.
24. Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 1996;141:214-224.